Bel Air Investment Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Bel Air Investment Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$48K	Buy	+17,000	New	+$44K	﹤0.01%	383

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bel Air Investment Advisors's LCTX Position: Q2 2021 in Review

Bel Air Investment Advisors opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2021: 17,000 shares worth $48K. The stake represents ﹤0.01% of the portfolio and ranks #383 among its holdings.

115 funds tracked by Wall St. Rank hold LCTX as of Q2 2021.

Bel Air Investment Advisors held 17,000 shares of Lineage Cell Therapeutics worth $48K as of Q2 2021.
Lineage Cell Therapeutics was a new Bel Air Investment Advisors position in Q2 2021.
Lineage Cell Therapeutics made up ﹤0.01% of Bel Air Investment Advisors's portfolio in Q2 2021, its #383 holding.
115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2021.

Based on Bel Air Investment Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.